p38α MAPK Inhibitor Selection for Tau-Negative DLB Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no approved therapies to effectively treat Dementia with Lewy Bodies (DLB) that do not involve substantial tau pathology, and existing treatments for DLB often fail to address synaptic dysfunction and neuronal loss.
Innovation Solution
Administering a selective p38α mitogen-activated protein kinase (MAPK) inhibitor, such as neflamapimod, to patients with DLB who have no substantial tau pathology, characterized by specific biomarkers like low levels of phosphorylated tau in plasma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for DLB are used, then some symptomatic relief may be achieved, but they fail to address synaptic dysfunction and neuronal loss effectively
Solution Approach 1:
The patent changes the therapeutic parameter by targeting p38α MAPK specifically rather than using non-specific treatments. This selective inhibition of p38α MAPK signaling pathway addresses the underlying synaptic dysfunction and neuronal loss mechanisms in DLB patients without substantial tau pathology, thereby improving treatment effectiveness while reducing harmful effects.
Solution Approach 2:
The patent extracts and targets the specific problematic pathway (p38α MAPK) that drives synaptic dysfunction and neuronal loss in DLB. By isolating and inhibiting this specific pathway rather than treating all symptoms generally, the treatment effectively addresses the root cause of harmful effects while maintaining reliability.
2Object-generated harmful factors
If a selective p38α MAPK inhibitor is administered to DLB patients with substantial tau pathology, then synaptic dysfunction may be addressed, but treatment effectiveness is reduced or inappropriate
Solution Approach 1:
The patent applies local quality by tailoring the treatment to specific patient subgroups based on their tau pathology status. Patients without substantial tau pathology receive p38α MAPK inhibition for optimal effect, while patients with substantial tau pathology are identified as a different group. This localized approach ensures treatment effectiveness is maintained for the appropriate patient population while avoiding misuse in inappropriate cases.
Solution Approach 2:
Instead of treating all DLB patients uniformly, the patent inverts the approach by first excluding patients with substantial tau pathology from this specific treatment. This inverse selection strategy ensures that the treatment is applied only where it is most effective, thereby maintaining high treatment reliability for the target population.
3Adaptability or versatility
If plasma ptau levels are used as a biomarker to identify patients without substantial tau pathology, then appropriate patient selection is enabled, but measurement complexity increases
Solution Approach 1:
The patent uses plasma ptau levels as an intermediary biomarker to indirectly assess tau pathology in the brain. This mediator approach allows accurate patient selection without requiring direct brain biopsy or complex imaging, thereby maintaining high patient selection accuracy while avoiding the most difficult measurement approaches.
Solution Approach 2:
The patent replaces complex direct assessment of tau pathology with a simpler blood-based biomarker measurement. Instead of requiring invasive brain procedures or complex neuroimaging to detect tau pathology, the system substitutes a minimally invasive plasma test that provides sufficient information for patient selection, thereby reducing measurement difficulty while maintaining accuracy.
Data Source
AI summary
The present invention provides methods and compositions for the treatment of subjects that have Dementia with Lewy Bodies (DLB) but have no substantial tau pathology. Subjects with DLB that have no substantial tau pathology are shown to be particularly responsive to treatment with a selective p38α mitogen activated protein kinase (MAPK) inhibitor compared to subjects with DLB that have substantial tau pathology.